To better understand the role played by MAO-B inhibitors in the treatment of glioma, the aim is to evaluate two newly synthesized compounds, namely Cmp3 and Cmp5 (Figure 1) [6], along with two approved selective MAO-B inhibitors (deprenyl and safinamide). This evidence concerns the gene MAOB and central nervous system cancer.